Joshua Lang, MD, MS

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Gilead
    Date added:
    Date updated:
    02/22/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    AstraZeneca
    Date added:
    Date updated:
    02/22/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    4D Pharma
    Date added:
    Date updated:
    02/22/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    sanofi
    Date added:
    Date updated:
    02/22/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Astellas
    Date added:
    Date updated:
    02/22/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Jansen
    Date added:
    Date updated:
    02/22/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Pfizer
    Date added:
    Date updated:
    02/22/2023
  • Attribution:
    Self
    Type of financial relationship:
    Stock Options (Non-urology Healthcare Related)
    Ineligible company:
    Salus Discovery, LLC
    Date added:
    Date updated:
    02/22/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Foundation Medicine
    Date added:
    Date updated:
    02/22/2023
Return to The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion (2023)